Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6295 | TAT 14 |
| Nrf2 activator; inhibits Nrf2/Keap1 interaction. Induces upregulation of Nrf2 pathway downstream gene expression including heme-oxygenase 1. Suppresses LPS-induced TNF-α expression in THP-1 cells. | |
| BCC6299 | PF 04418948 |
| Potent EP2 receptor antagonist (IC50 = 16 nM for human EP2 receptors). Displays over 2000-fold selectivity for EP2 receptors over EP1, EP3, EP4, DP1 amd CRTH2 receptors; exhibits <30% binding at a diverse panel of GPCRs and ion channels at a concentration of 10 μM. Inhibits PGE2-induced increases in intracellular cAMP; reverses PGE2-invoked relaxation of mouse trachea (IC50 = 2.7 nM). | |
| BCC6301 | TC ASK 10 |
| Potent ASK1 inhibitor (IC50 = 14 nM); displays selectivity for ASK1 over other kinases including ASK2 (IC50 = 0.51 μM), MEKK1, TAK1, IKKβ, ERK1, JNK1, p38α, GSK-3β, PKCθ and B-raf (IC50 values are > 10 μM). Blocks downstream JNK1/p38 phosphorylation in cells. Orally bioavailable. | |
| BCC6302 | HJC 0350 |
| Selective Epac2 inhibitor (IC50 = 0.3 μM). Displays no effect on Epac1. Blocks stimulation of the Epac2-FL FRET sensor in HEK293 cells. | |
| BCC6307 | NS 6180 |
| Potent KCa3.1 channel blocker (IC50 values are 9, 14 and 15 nM for rat, human and mouse erythrocyte KCa3.1 channels respectively). Exhibits ~ 50% inhibition of KCa1.1, KV1.3, and KV11.1 channels, noradrenaline and dopamine transporters, L-type Ca2+ channels and melatonin receptors at a concentration of 10 μM. Potently inhibits IL-2 and IFN-γ production in rat lymphocytes (IC50 ~ 50 nM); reduces DBNS-induced experimental colitis in rats. | |
| BCC6308 | ML 190 |
| Selective κ opioid receptor (KOP) antagonist (IC50 = 120 nM in a β-arrestin assay); displays >267-fold selectivity over μ and δ opioid receptors. | |
| BCC6309 | SR 1001 |
| Retinoic acid receptor-related orphan receptor (ROR) α and γ inverse agonist (Ki values are 172 and 111 nM for RORα and RORγ respectively). Demonstrates no activity at RORβ or LXR. Suppresses Th17 cell differentiation and cytokine expression and reduces the severity of disease in an animal model of mulitple sclerosis. | |
| BCC6310 | SR 2211 |
| Selective inverse agonist of retinoic acid receptor-related orphan receptor γ (RORγ) (Ki = 105 nM; IC50 ~320 nM). Exhibits weak activity at liver X receptor α (LXRα); does not affect the transcriptional activity of farnesoid X receptors (FXR), and has no impact on the transcriptional activity of RORα. | |
